Last reviewed · How we verify
AZD1419
AZD1419 is a recombinant human angiopoietin-2 (Ang-2) decoy receptor.
AZD1419 is a recombinant human angiopoietin-2 (Ang-2) decoy receptor. Used for Geographic atrophy secondary to age-related macular degeneration.
At a glance
| Generic name | AZD1419 |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Angiopoietin-2 decoy receptor |
| Target | Ang-2 decoy receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
AZD1419 works by binding to Ang-2, thereby inhibiting its interaction with its receptor Tie2, which plays a role in angiogenesis and inflammation. This mechanism of action is thought to contribute to its therapeutic effects in various diseases.
Approved indications
- Geographic atrophy secondary to age-related macular degeneration
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Conjunctival hyperemia
Key clinical trials
- AZD1419 Ph2a Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD1419 CI brief — competitive landscape report
- AZD1419 updates RSS · CI watch RSS
- AstraZeneca portfolio CI